Eye muscle antibodies in Graves' ophthalmopathy: pathogenic or secondary epiphenomenon?
- PMID: 15164997
- DOI: 10.1007/BF03345270
Eye muscle antibodies in Graves' ophthalmopathy: pathogenic or secondary epiphenomenon?
Abstract
The extra ocular (eye) muscles are one of the principal tissues involved in the autoimmune-mediated inflammation of Graves' ophthalmopathy (GO). Several eye muscle proteins are targeted by autoantibodies or sensitized T lymphocytes, or both, and include: G2s, which is now identified as the terminal 141 amino acids of the winged-helix transcription factor FOXP1, the flavoprotein (Fp) subunit of the mitochondrial enzyme succinate dehydrogenase, the so-called "64kDa protein", a non-tissue specific membrane protein called 1D and the calcium binding protein calsequestrin. Of these, antibodies against G2s and Fp are the most sensitive markers of eye muscle damage in patients with thyroid autoimmunity even though neither antigen is specific to eye muscle and neither antibody is specific to GO. However, the recent finding that the calsequestrin gene is 4.7 times more expressed in eye muscles than other skeletal muscles suggests that we should reconsider the possible role of anti-calsequestrin autoantibodies in ophthalmopathy. GO may comprise two main subtypes with different pathogenetic mechanisms, namely ocular myopathy in which eye muscle inflammation predominates and congestive ophthalmopathy where inflammatory changes occur in the periorbital connective tissues in the absence of eye muscle dysfunction. Anti-G2s and anti-Fp antibodies are closely associated with the ocular myopathy subtype of GO while antibodies targeting type XIII collagen, the only member of the collagen family to have a transmembrane domain, are closely linked to congestive ophthalmopathy. Since both G2s and Fp are intracellular antigens it is unlikely that either antibody causes eye muscle fiber damage in GO, although a role in the later stages of the disease when the fiber has released its cellular contents has not been excluded. Eye muscle antibodies that are cytotoxic to eye muscle cells in antibody-dependent cell-mediated cytotoxicity (ADCC) are more likely to play a role in eye muscle fiber damage since they target a putative eye muscle cell membrane antigen, the identity of which is currently being investigated. While anti-G2s and anti-Fp antibodies are probably secondary to an underlying reaction, such as cytotoxic T lymphocyte targeting of an eye muscle membrane antigen that has yet to be identified, they are reliable markers of immunologically mediated eye muscle fiber damage in patients with Graves' hyperthyroidism. In conclusion, while a pathogenic role for eye muscle antibodies has not been excluded, they are most likely secondary to cytotoxic T cell reactions in GO and, as such, good markers of this autoimmune disease.
Similar articles
-
Study of serum antibodies against three eye muscle antigens and the connective tissue antigen collagen XIII in patients with Graves' disease with and without ophthalmopathy: correlation with clinical features.Thyroid. 2006 Oct;16(10):967-74. doi: 10.1089/thy.2006.16.967. Thyroid. 2006. PMID: 17042681
-
Eye muscle antibodies and subtype of thyroid-associated ophthalmopathy.Thyroid. 2002 Mar;12(3):187-91. doi: 10.1089/105072502753600115. Thyroid. 2002. PMID: 11952037
-
Cloning and characterization of the novel thyroid and eye muscle shared protein G2s: autoantibodies against G2s are closely associated with ophthalmopathy in patients with Graves' hyperthyroidism.J Clin Endocrinol Metab. 2000 Apr;85(4):1641-7. doi: 10.1210/jcem.85.4.6553. J Clin Endocrinol Metab. 2000. PMID: 10770210
-
[Pathogenesis of thyroid eye disease - does autoimmunity against the TSH receptor explain all cases?].Endokrynol Pol. 2011;62 Suppl 1:1-7. Endokrynol Pol. 2011. PMID: 22125104 Review. Polish.
-
Thyroid-associated ophthalmopathy: clinical features, pathogenesis, and management.Crit Rev Clin Lab Sci. 2000 Dec;37(6):523-49. doi: 10.1080/10408360091174303. Crit Rev Clin Lab Sci. 2000. PMID: 11192331 Review.
Cited by
-
Rituximab treatment in patients with active Graves' orbitopathy: effects on proinflammatory and humoral immune reactions.Clin Exp Immunol. 2010 Sep;161(3):436-43. doi: 10.1111/j.1365-2249.2010.04191.x. Clin Exp Immunol. 2010. PMID: 20529087 Free PMC article. Clinical Trial.
-
Antibodies targeting the calcium binding skeletal muscle protein calsequestrin are specific markers of ophthalmopathy and sensitive indicators of ocular myopathy in patients with Graves' disease.Clin Exp Immunol. 2006 Jul;145(1):56-62. doi: 10.1111/j.1365-2249.2006.03110.x. Clin Exp Immunol. 2006. PMID: 16792674 Free PMC article.
-
Pathogenesis of Graves' ophthalmopathy: the role of autoantibodies.Thyroid. 2007 Oct;17(10):1013-8. doi: 10.1089/thy.2007.0185. Thyroid. 2007. PMID: 17935483 Free PMC article. Review.
-
Graves' ophthalmopathy: state of the art and perspectives.J Endocrinol Invest. 2004 Mar;27(3):295-301. doi: 10.1007/BF03345280. J Endocrinol Invest. 2004. PMID: 15165007 Review.
-
Increased expression of TSH receptor by fibrocytes in thyroid-associated ophthalmopathy leads to chemokine production.J Clin Endocrinol Metab. 2012 May;97(5):E740-6. doi: 10.1210/jc.2011-2514. Epub 2012 Mar 7. J Clin Endocrinol Metab. 2012. PMID: 22399514 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources